talazoparib

Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
Yahoo/Zacks.com
Myriad Genetics
FDA
BRACAnalysis CDx
diagnostics
Pfizer
talazoparib
Flag link:
Can This Pharma's $14 Billion Bet Succeed?
Can This Pharma's $14 Billion Bet Succeed?
Motley Fool
Pfizer
M&A
Medivation
Xtandi
talazoparib
Flag link:
Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission
Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission
CP Wire
Pfizer
talazoparib
BRCA-mutant breast cancer
breast cancer
metastatic breast cancer
FDA
EMA
priority review
Flag link:
Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission
Pfizer
talazoparib
BRCA-mutant breast cancer
breast cancer
Flag link:
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
Flag link:
Array Biopharma ties up with Pfizer on cancer-fighting combos
Array Biopharma ties up with Pfizer on cancer-fighting combos
Fierce Biotech
Array Biopharma
Pfizer
clinical trials
binimetinib
talazoparib
Merck KGaA
Bavencio
cancer
Flag link:
A New PARP Drug For Breast Cancer
A New PARP Drug For Breast Cancer
Forbes
PARP inhibitors
breast cancer
metastatic breast cancer
talazoparib
Pfizer
Flag link:
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
Endpoints
Pfizer
AstraZeneca
talazoparib
advanced breast cancer
Lynparza
PARP inhibitors
Flag link:
What Pfizer Gets in Its $14 Billion Medivation Deal
What Pfizer Gets in Its $14 Billion Medivation Deal
Motley Fool
Pfizer
Medivation
M&A
Xtandi
prostate cancer
talazoparib
pidilizumab
Flag link:
Pfizer spent $14 billion on a company with just one approved drug — here's why that's a game changer
Pfizer spent $14 billion on a company with just one approved drug — here's why that's a game changer
Yahoo/Business Insider
Pfizer
Medivation
M&A
Sanofi
Xtandi
prostate cancer
pidilizumab
talazoparib
Flag link:
Buyout target Medivation says cancer drug could be "best in class"
Buyout target Medivation says cancer drug could be "best in class"
Yahoo/Reuters
Medivation
talazoparib
PARP inhibitors
Sanofi
M&A
Flag link:
Medivation: It’s Not Just M&A
Medivation: It’s Not Just M&A
Barron's
Medivation
M&A
AstraZenca
Sanofi
Gilead Sciences
talazoparib
PARP inhibitors
Flag link:
3 Cancer Companies to Watch Closely in 2016
3 Cancer Companies to Watch Closely in 2016
Motley Fool
cancer
Celldex
Medivation
Clovis Oncology
rociletinib
talazoparib
Rintega
Flag link:
Medivation Destined To Become A Biotech Behemoth As Low-Risk Pipeline Expands
Medivation Destined To Become A Biotech Behemoth As Low-Risk Pipeline Expands
Seeking Alpha
talazoparib
Medivation
Xtandi
pidilizumab
Flag link:
BioMarin sells its PhIII cancer drug to Medivation for $570M
BioMarin sells its PhIII cancer drug to Medivation for $570M
Fierce Biotech
Biomarin
Medivation
talazoparib
breast cancer
BRCA1
BRCA2
Flag link: